CLYM116 Phase 1 Data Shows Best-in-Class APRIL Suppression, Q12W Dosing in IgA Nephropathy
CLYM has more than doubled off its 52-week low of $1.54.
Summary
Climb Bio reported positive Phase 1 data for CLYM116, its anti-APRIL antibody for IgA nephropathy. A single 320 mg dose achieved >90% APRIL suppression and 60-75% reductions in IgA/Gd-IgA1 through 12 weeks, with a ~29-day half-life supporting every-12-week dosing. No serious adverse events or hypogammaglobulinemia were observed. The company is advancing a Phase 2 NAVIGATE-2 trial with initial data expected in H1 2027 and Phase 3 initiation planned for 2027. This is the first clinical data for CLYM116 and positions it as a potential best-in-class therapy in a competitive IgAN market. The webcast today at 8:00 a.m. ET will provide additional detail.
At the time of this announcement, CLYM was trading at $15.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $864.4M. The 52-week trading range was $1.54 to $18.33. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.